Ratings by Oppenheimer (Matthew Biegler)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/24/2026 | ORIC Pharmaceuticals | ORIC | Maintain | Outperform (N/A) |
|
Details | ||
| 12/4/2025 | Ascentage Pharma Group | AAPG | New Coverage | Outperform (N/A) |
30.33 (23.14) |
-23.71% | Details | |
| 11/14/2025 | ORIC Pharmaceuticals | ORIC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/10/2025 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/1/2025 | Fulcrum Therapeutics | FULC | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/8/2025 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 9/3/2025 | Olema Pharmaceuticals | OLMA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2025 | Acrivon Therapeutics Inc | ACRV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2025 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2025 | CytomX Therapeutics | CTMX | New Coverage | Outperform (N/A) |
2.32 (4.68) |
101.72% | Details | |
| 7/10/2025 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2025 | Blueprint Medicines | BPMC | Downgrade | Perform (Outperform) |
101.35 (129.46) |
27.74% | Details | |
| 6/2/2025 | Aquestive Therapeutics | AQST | New Coverage | Outperform (N/A) |
2.71 (4.22) |
55.72% | Details | |
| 5/15/2025 | Acrivon Therapeutics Inc | ACRV | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2025 | Olema Pharmaceuticals | OLMA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2025 | Olema Pharmaceuticals | OLMA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2025 | Arvinas Inc. | ARVN | Downgrade | Perform (Outperform) |
17.56 (13.60) |
-22.55% | Details | |
| 2/12/2025 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2024 | Fate Therapeutics | FATE | Maintain | Perform (N/A) |
|
Details | ||
| 10/31/2024 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2024 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2024 | ORIC Pharamceuticals | ORIC | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2024 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2024 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/8/2024 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/8/2024 | Blueprint Medicines | BPMC | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/2/2024 | Cartesian Therapeutics | RNAC | Downgrade | Perform (Outperform) |
24.27 (6.85) |
-71.78% | Details | |
| 5/16/2024 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2024 | Acrivon Therapeutics Inc | ACRV | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2024 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2024 | Vor Biopharma, Inc. | VOR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/21/2024 | Vor Biopharma, Inc. | VOR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2024 | ORIC Pharamceuticals | ORIC | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2024 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/20/2024 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/31/2024 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2023 | Blueprint Medicines | BPMC | Upgrade | Outperform (Perform) |
55.22 (129.46) |
134.44% | Details | |
| 8/11/2023 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2023 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 7/21/2023 | Olema Pharmaceuticals | OLMA | New Coverage | Outperform (N/A) |
9.14 (21.55) |
135.78% | Details | |
| 6/26/2023 | Nurix | NRIX | New Coverage | Outperform (N/A) |
10.19 (15.10) |
48.18% | Details | |
| 6/26/2023 | Arvinas Inc. | ARVN | New Coverage | Outperform (N/A) |
26.79 (17.56) |
-34.45% | Details | |
| 6/12/2023 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2023 | Acrivon Therapeutics Inc | ACRV | New Coverage | Outperform (N/A) |
11.78 (1.55) |
-86.84% | Details | |
| 6/2/2023 | Ambrx Biopharma | AMAM | New Coverage | Outperform (N/A) |
14.76 (28.00) |
89.7% | Details | |
| 5/16/2023 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2023 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2023 | ORIC Pharamceuticals | ORIC | Upgrade | Outperform (Perform) |
4.65 (13.71) |
194.84% | Details | |
| 2/27/2023 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 12/22/2022 | Nkarta Inc. | NKTX | Downgrade | Perform (Outperform) |
5.88 (2.50) |
-57.48% | Details | |
| 12/22/2022 | Fate Therapeutics | FATE | Downgrade | Perform (Outperform) |
12.25 (1.33) |
-89.14% | Details | |
| 12/22/2022 | Celularity | CELU | Downgrade | Perform (Outperform) |
1.28 (1.21) |
-5.47% | Details | |
| 12/12/2022 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/30/2022 | Portage Biotech inc. | PRTG | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2022 | Celularity | CELU | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2022 | Vor Biopharma, Inc. | VOR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2022 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2022 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Blueprint Medicines | BPMC | Downgrade | Perform (Outperform) |
48.24 (129.46) |
168.37% | Details | |
| 9/7/2022 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/1/2022 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2022 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2022 | Medicenna Therapeutics | MDNA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/18/2022 | Portage Biotech inc. | PRTG | New Coverage | Outperform (N/A) |
9.01 (6.81) |
-24.42% | Details | |
| 7/18/2022 | ORIC Pharamceuticals | ORIC | New Coverage | Perform (N/A) |
4.27 (13.71) |
221.08% | Details | |
| 7/18/2022 | Ideaya Biosciences | IDYA | New Coverage | Outperform (N/A) |
15.50 (33.19) |
114.13% | Details | |
| 7/8/2022 | Blueprint Medicines | BPMC | New Coverage | Outperform (N/A) |
54.28 (129.46) |
138.5% | Details | |
| 6/23/2022 | Medicenna Therapeutics | MDNA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2022 | Turning Point Therapeutics Inc. | TPTX | Downgrade | Perform (Outperform) |
34.16 (76.01) |
122.51% | Details | |
| 3/18/2022 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2022 | Vor Biopharma, Inc. | VOR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2022 | Fulcrum Therapeutics | FULC | New Coverage | Outperform (N/A) |
13.03 (8.17) |
-37.3% | Details | |
| 2/22/2022 | Homology Medicines | FIXX | Downgrade | Perform (Outperform) |
3.86 (0.93) |
-75.91% | Details | |
| 2/17/2022 | Marker Therapeutics | MRKR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2022 | Celularity | CELU | New Coverage | Outperform (N/A) |
4.17 (1.21) |
-70.98% | Details | |
| 1/21/2022 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2021 | Vor Biopharma, Inc. | VOR | New Coverage | Outperform (N/A) |
11.54 (15.12) |
31.02% | Details | |
| 11/16/2021 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2021 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/13/2021 | Homology Medicines | FIXX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/16/2021 | Nkarta Inc. | NKTX | New Coverage | Outperform (N/A) |
27.77 (2.50) |
-91% | Details | |
| 4/6/2021 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2021 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/19/2021 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2021 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/18/2020 | Medicenna Therapeutics | MDNA | New Coverage | Outperform (N/A) |
3.82 (0.16) |
-95.81% | Details | |
| 11/13/2020 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2020 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/26/2020 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2020 | Marker Therapeutics | MRKR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2020 | Homology Medicines | FIXX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/10/2020 | Turning Point Therapeutics Inc. | TPTX | New Coverage | Outperform (N/A) |
62.77 (34.16) |
-45.58% | Details | |
| 6/10/2020 | Fate Therapeutics | FATE | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/16/2020 | Homology Medicines | FIXX | Upgrade | Outperform (Perform) |
14.06 (0.93) |
-93.39% | Details | |
| 3/11/2020 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/12/2020 | Marker Therapeutics | MRKR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/17/2020 | Aptose Biosciences | APTO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2019 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2019 | Marker Therapeutics | MRKR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2019 | Homology Medicines | FIXX | New Coverage | Perform (N/A) |
12.84 (14.06) |
9.5% | Details | |
| 7/3/2019 | Marker Therapeutics | MRKR | New Coverage | Outperform (N/A) |
8.07 (1.38) |
-82.9% | Details | |
| 1/25/2019 | Aptose Biosciences | APTO | New Coverage | Outperform (N/A) |
2.08 (1.71) |
-17.79% | Details |
